Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × irinotecan sucrosofate × Endocrine × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 40 Thoracic 5 Head & Neck 3 Sarcoma 2 Breast 2 Tumor-Agnostic 1 Other solid neoplasm 1 Endocrine 1 CNS 1

Conditions

Neoplasms 1 Carcinoma, Neuroendocrine 1

Interventions

Everolimus 25 lutetium Lu 177 dotatate 21 pembrolizumab 19 Temozolomide 18 Cisplatin 14 Magnetic Resonance Spectroscopy 13 Sunitinib 12 Nivolumab 12 lenvatinib 11 cabozantinib 11 Specimen Handling 11 Capecitabine 10 Sorafenib 9 Etoposide 9 Bevacizumab 9 trametinib 7 pasireotide 7 lanreotide 7 dabrafenib 7 Paclitaxel 7 Octreotide 7 Ipilimumab 7 Carboplatin 7 pazopanib 6 Irinotecan 6 gallium Ga 68 dotatate 5 Mitotane 5 Injections 5 Fluorodeoxyglucose F18 5 surufatinib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03837977 2024-12-30

NET02

The Christie NHS Foundation Trust

Phase 2 Completed

Neoplasms, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡